Emerging Anabolic Therapies for Osteoporosis

키워드

참고문헌 (50)

1. Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)
2. Kang HY, "Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data", BMC Public Health, 10, pp.230~ (2010)
3. 윤현구, "Incidence and Mortality Following Hip Fracture in Korea", Journal of Korean Medical Science, 26(8), pp.1087~1092 (2011), 대한의학회
4. Black DM, "Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348(9041), pp.1535~1541 (1996)
5. Cummings SR, "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial", JAMA, 280, pp.2077~2082 (1998)
6. Harris ST1, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group", JAMA, 282, pp.1344~1352 (1999)
7. Black DM, "Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial. FIT Research Group", J Clin Endocrinol Metab, 85, pp.4118~4124 (2000)
8. McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
9. Black DM, "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis", N Engl J Med, 356, pp.1809~1822 (2007)
10. Baron R, "Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives", J Clin Endocrinol Metab, 97, pp.311~325 (2012)
11. Hollick RJ, "Role of bisphosphonates in the management of postmenopausal osteoporosis:an update on recent safety anxieties", Menopause Int, 17, pp.66~72 (2011)
12. Toulis KA, "Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis", Hormones, 10, pp.174~195 (2011)
13. Kraezlin ME, "Parathyroid hormone analogues in the treatment of osteoporosis", Nat Rev Endocrinol, 7, pp.647~656 (2011)
14. Baron R, "Wnt signaling in bone homeostasis and disease: from human mutations to treatments", Nat Med, 19, pp.179~192 (2013)
15. Hodsman AB, "Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use", Endocr Rev, 26, pp.688~703 (2005)
16. Clevers H., "Wnt", beta-catenin signaling in development and disease, 2006, pp.127, 469~480
17. Semenov MV, "SnapShot: Noncanonical Wnt Signaling Pathways", Cell, 131, pp.1378~ (2007)
18. Martin TJ, "Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis", steoporos Int, 19, pp.1125~1138 (2008)
19. Baron R, "Targeting the Wnt", beta-catenin pathway to regulate bone formation in the adult skeleton, 2007, pp.148, 2635~2643
20. Milat F, "Is Wnt signalling the final common pathway leading to bone formation?", Mol Cell Endocrinol, 310, pp.52~62 (2009)
21. Bodine PV, "The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice", Mol Endocrinol, 18, pp.1222~1237 (2004)
22. Mao B, "Kremen proteins are Dickkopf receptors that regulate Wnt", beta-catenin signaling, 2002, pp.417, 664~667
23. Semënov M, "SOST is a ligand for LRP5", LRP6 and a Wnt signaling inhibitor, 2005, pp.280, 26770~26775
24. Gong Y, "LDL receptorrelated protein 5 (LRP5) affects bone accrual and eye development", Cell, 107, pp.513~523 (2001)
25. Balemans W, "Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)", Hum Mol Genet, 10, pp.537~543 (2001)
26. Loots GG, "Genomic deletion of a longrange bone enhancer misregulates sclerostin in Van Buchem disease", Genome Res, 15, pp.928~935 (2005)
27. Neer RM, "Effect of PTH on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)
28. Ettinger B, "Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate", J Bone Miner Res, 19, pp.745~751 (2004)
29. Black DM, "One year of alendronate after one year of parathyroid hormone (1-84)for osteoporosis", N Engl J Med, 353, pp.555~565 (2005)
30. onceweekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk, "J Clin Endocrinol Metab", 2012, 3097~3106
31. Black DM, "Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling", J Clin Endocrinol Metab, 93, pp.2166~2172 (2008)
32. Daddona PE, "Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis", Pharm Res, 28, pp.159~165 (2011)
33. Cosman F, "Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women", J Clin Endocrinol Metab, 95, pp.151~158 (2010)
34. Strewler GJ, "The physiology of parathyroid hormone-related protein", N Engl J Med, 342, pp.177~185 (2000)
35. Wysolmerski JJ1, "Hypercalcemia of malignancy: the central role of parathyroid hormonerelated protein", Annu Rev Med, 45, pp.189~200 (1994)
36. Pedro Esbrit P, "Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies", Biochemical Pharmacology, 85, pp.1417~1423 (2013)
37. Horwitz MJ, "A comparison of PTHRP and PT on markers of bone turnover and bone density in postmenopausal women: The PrOP study", J Bone Miner Res, 28, pp.2266~2276 (2013)
38. Yates J, "The PTHrP1-34 analog, abaloparatide (BA058), induces consistent, marked and rapid increases in hip and spine BMD with compared to placebo and teriparatide", Abstract and oral presented at the Endocrine Society’s 96th Annual Meeting and Expo (2013)
39. Yates J, "A Transdermal patch delivering the PTHrP1-34 analog, abaloparatide (BA058), dosedependently increases spine and hip BMD compared to placebo", Abstract and oral presented at the Endocrine Society’s 96th Annual Meeting and Expo (2013)
40. Kumar S, "An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation", Bone, 46, pp.534~542 (2010)
41. Fitzpatrick LA, "The effect of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density", J Clin Endocrinol Metab, 96, pp.2441~2449 (2011)
42. Padhi D, "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody", J Bone Miner Res, 26, pp.19~26 (2011)
43. McClung MR, "Romosozumab in postmenopausal women with low bone mineral density", N Engl J Med, 370, pp.412~420 (2014)
44. Vahle JL, "Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety", Toxicol Pathol, 30, pp.312~321 (2002)
45. Kansara M, "Wnt inhibitory factor 1 is peigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice", J Clin Invest, 119, pp.837~851 (2009)
46. Edwards CM, "Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo", Blood, 111, pp.2833~2842 (2008)
47. Brunkow ME, "Bone dysplasia sclerosteosis result from loss of the SOST gene product, a novel cystine knot-containing protein", Am J Hum Genet, 68, pp.577~589 (2001)
48. Canalis E., "New treatment modalities in osteoporosis", Endocr Pract, 16, pp.855~863 (2010)
49. Gardner JC, "Bone mineral density in sclerosteosis: affected individuals and gene carriers", J Clin Endocrinol Metab, 90, pp.6392~6395 (2005)
50. van Lierop AH, "Patients with sclerosteosis and disease carriers:human models of the effect of sclerostin on bone turnover", J Bone Miner Res, 26, pp.2804~2811 (2011)

관련 논문AI추천